Alligator Bioscience AB - Asset Resilience Ratio
Alligator Bioscience AB (ATORX) has an Asset Resilience Ratio of 56.24% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2007–2025)
This chart shows how Alligator Bioscience AB's Asset Resilience Ratio has changed over time. Check Alligator Bioscience AB strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Alligator Bioscience AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ATORX market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr62.20 Million | 56.24% |
| Short-term Investments | Skr0.00 | 0% |
| Total Liquid Assets | Skr62.20 Million | 56.24% |
Asset Resilience Insights
- Very High Liquidity: Alligator Bioscience AB maintains exceptional liquid asset reserves at 56.24% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Alligator Bioscience AB Industry Peers by Asset Resilience Ratio
Compare Alligator Bioscience AB's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Syndax Pharmaceuticals Inc
NASDAQ:SNDX |
Biotechnology | 46.79% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 63.47% |
|
Chengdu Kanghua Biological Products
SHE:300841 |
Biotechnology | 1.19% |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Alligator Bioscience AB (2007–2025)
The table below shows the annual Asset Resilience Ratio data for Alligator Bioscience AB.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 56.24% | Skr62.20 Million ≈ $6.69 Million |
Skr110.60 Million ≈ $11.90 Million |
-5.40pp |
| 2024-12-31 | 61.64% | Skr64.31 Million ≈ $6.92 Million |
Skr104.34 Million ≈ $11.23 Million |
+5.82pp |
| 2023-12-31 | 55.82% | Skr66.12 Million ≈ $7.12 Million |
Skr118.45 Million ≈ $12.75 Million |
-1.56pp |
| 2022-12-31 | 57.38% | Skr97.31 Million ≈ $10.47 Million |
Skr169.58 Million ≈ $18.25 Million |
-26.10pp |
| 2021-12-31 | 83.48% | Skr278.15 Million ≈ $29.93 Million |
Skr333.20 Million ≈ $35.86 Million |
+15.46pp |
| 2020-12-31 | 68.02% | Skr103.34 Million ≈ $11.12 Million |
Skr151.94 Million ≈ $16.35 Million |
-28.36pp |
| 2019-12-31 | 96.38% | Skr299.85 Million ≈ $32.27 Million |
Skr311.13 Million ≈ $33.48 Million |
+20.98pp |
| 2018-12-31 | 75.40% | Skr383.13 Million ≈ $41.23 Million |
Skr508.16 Million ≈ $54.69 Million |
+1.85pp |
| 2017-12-31 | 73.55% | Skr472.92 Million ≈ $50.89 Million |
Skr643.03 Million ≈ $69.20 Million |
-20.51pp |
| 2016-12-31 | 94.06% | Skr659.14 Million ≈ $70.93 Million |
Skr700.78 Million ≈ $75.42 Million |
+94.06pp |
| 2015-12-31 | 0.00% | Skr1.00K ≈ $107.62 |
Skr416.26 Million ≈ $44.80 Million |
-51.18pp |
| 2008-12-31 | 51.18% | Skr10.00 Million ≈ $1.08 Million |
Skr19.54 Million ≈ $2.10 Million |
-29.54pp |
| 2007-12-31 | 80.72% | Skr38.62 Million ≈ $4.16 Million |
Skr47.85 Million ≈ $5.15 Million |
-- |
About Alligator Bioscience AB
Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Belgium. The company develops Mitazalimab, a stimulatory antibody that targets CD40, which is in phase 3 clinical trial for the treatment of solid metastatic tumors, including pancreatic cancer; and ATOR-4066, tumor-directed bispecific antibody, developed using N… Read more